Randomized comparison of novel biodegradable polymer and durable polymer‐coated cobalt‐chromium sirolimus‐eluting stents: Three‐Year Outcomes of the I‐LOVE‐IT 2 Trial. Issue Volume 91:Issue S1(2018) (11th January 2018)

• Record Type: Journal Article
• Authors: Song, Lei; Li, Jing; Guan, Changdong; Jing, Quanmin; Lu, Shuzheng; Yang, Lixia; Xu, Kai; Yang, Yuejin; Xu, Bo; Han, Yaling
• Other Names: Gao Runlin guestEditor.
• Is Part Of: Catheterization and cardiovascular interventions. Volume 91:Issue S1(2018)
• Page Start: 608
• Page End: 616
• Publication Date: 2018-01-11
• Subjects: biodegradable polymer -- drug‐eluting stent -- durable polymer -- sirolimus‐eluting stent; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.27465
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: We aimed to compare the long‐term outcomes of the novel biodegradable polymer cobalt‐chromium sirolimus‐eluting stent (BP‐SES) versus the durable polymer sirolimus‐eluting stent (DP‐SES) in the I‐LOVE‐IT2 trial. Backgrounds: Comparisons of the long‐term safety and efficiency of the BP‐DES versus the DP‐DES are limited. Methods: A total of 2, 737 patients eligible for coronary stenting were randomized to the BP‐SES or DP‐SES group at a 2:1 ratio. The primary endpoint of target lesion failure (TLF) was defined as a composite of cardiac death, target vessel myocardial infarction (MI), or clinically indicated target lesion revascularization. Results: A three‐year clinical follow‐up period was available for 2, 663 (97.3%) patients. There were no significant differences in TLF (8.9% vs. 8.6%, P = 0.81), patient‐oriented composite endpoint (PoCE) (15.2% vs.14.5%, P = 0.63), or individual components between the BP‐SES and DP‐SES. Definite/probable stent thrombosis (ST) was low and similar at 3 years (0.8% vs. 1.0%, P = 0.64). Landmark analysis of 1–3 years showed that the TLF (2.7% vs. 2.6%, P = 0.81), PoCE (6.2% vs. 5.1%, P = 0.28), and definite/probable ST (0.4% vs. 0.4%, P = 1.00) were comparable between the 2 arms. Conclusions: In this prospective randomized trial, the BP‐SES showed similar clinical results versus the DP‐SES in terms of safety and efficacy outcomes over a 3‐year follow‐up period.